Based on the studies discussed above and recently proposed expert recommendations on the appropriate use of blood biomarkers, including phosphorylated tau (p-tau), in clinical practice [16, 17], this systematic review has two specific objectives focused on GFAP as an important upstream factor during AD development. Here, MAPT is linked to Alzheimer disease.